Cullinan Oncology Announces U.S. FDA Clearance of …
WEBMar 1, 2024 · Cullinan Oncology, Inc. Company will initiate Phase 1 study of CLN-619 for relapsed or refractory multiple myeloma, first MICA/B antibody clinical study in hematologic malignancies.
Cullinan Shifts Focus From Oncology To Autoimmune Disorders, …
WEBApr 16, 2024 · Cullinan Therapeutics Inc (NASDAQ: CGEM), formerly Cullinan Oncology Inc, announced its plans to expand into autoimmune diseases and intends to pursue the development of CLN-978 in autoimmune...
Cullinan Therapeutics Presents Positive Updated Data from
WEB6 days ago · Cullinan entered into a partnership with Taiho in 2022, receiving an upfront cash payment of $275M and the potential for additional payments totaling $130M to be made for the achievement of U.S. regulatory milestones. Cullinan also retains a 50/50 profit share in the U.S. ... BioSpace is the digital hub for life science news and jobs. We ...
Cullinan Therapeutics Announces Strategic Expansion into …
WEBApr 16, 2024 · Cullinan Therapeutics, Inc. CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication. Clinical observations from CLN...
Cullinan changes name, pivots to autoimmune disease
WEBApr 16, 2024 · Cullinan Therapeutics said Tuesday that it’s expanding into autoimmune diseases such as lupus on the heels of promising research in the cell therapy field. As part of the new focus, the company shed its old name, Cullinan Oncology, and adopted a new logo and website address.
News Releases - Cullinan Therapeutics, Inc.
WEBApr 16, 2024 · Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results. August 8, 2024. Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib. June 1, 2024. Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen …
Cullinan Therapeutics | Modality-Agnostic Targeted Therapeutics
WEBPartner With Us. Read the latest news and information from Cullinan Therapeutics. Collaboration is key to how we work at Cullinan Therapeutics. The closer we work together—across teams, programs, backgrounds, and experiences—the better we can challenge the status quo.
Cullinan Therapeutics to Present First Data for CLN-619, a
WEBCAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today...
Cullinan Therapeutics Announces Positive Initial Data from
WEBCAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today...
Cullinan Oncology Provides Corporate Update and ... - Markets …
WEBMar 14, 2024 · Cullinan expects to provide a clinical data update from the ongoing Phase 1 dose escalation study in patients with advanced solid tumors in the second half of 2024. CLN-617 (IL-2 and IL-12 ...
Skip to content